

## General

### Title

Use of opioids from multiple providers or at high dosage in persons without cancer: the proportion of individuals without cancer receiving prescriptions for opioids from four (4) or more prescribers AND four (4) or more pharmacies.

### Source(s)

Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p.

## Measure Domain

### Primary Measure Domain

Related Health Care Delivery Measures: Use of Services

### Secondary Measure Domain

Does not apply to this measure

## Brief Abstract

### Description

This measure is used to assess the proportion (XX out of 1,000) of individuals 18 years and older without cancer receiving prescriptions for opioids from four (4) or more prescribers AND four (4) or more pharmacies.

### Rationale

The purpose of quality measurement is to improve quality, inform consumers, reduce risk to patients and influence payment. At this time, the goal is to develop measure concepts that are indicative of potential improvements in or to our healthcare system so that evidence-based patient care can be provided and patient outcomes can be achieved, in consideration of costs and, ultimately, value.

Towards this end, the Pharmacy Quality Alliance (PQA) proposes 3 measures related to opioid use that are indicative of the quality of care for these medications. PQA proposes these measures to examine the

quality of use related to the dose of the medications over time, access to the medications and the combination of both of these criteria.

Claims data from commercially insured patients indicate that approximately 8% of opioid prescriptions for acute pain and 12% for chronic pain specify a daily dosage of 120 morphine equivalent dose (MED) or more (Office of Disease Prevention and Health Promotion, 2014). The proportion of patients being treated at this dosage for more than 90 days has not been described. However, one study of veterans treated with 180 MED/day or more for 90+ days (Liu et al., 2013) found that this group was characterized by high rates of psychiatric and substance abuse disorders and frequently did not receive care consistent with clinical guidelines. Other studies have suggested the people at high opioid dosage are at greater risk of overdoses and fractures (Morasco et al., 2010; Washington State Agency Medical Directors Group, 2010; Dunn et al., 2010). The Washington State Agency Medical Directors Group has suggested 120 MED as a dosage level that should not be exceeded without special consideration (Paulozzi et al., 2012).

Prescription drug monitoring programs, which track the use of multiple providers by patients, indicate that such use is typically found among a small proportion of patients, with the proportion declining as the number of providers increases. In Massachusetts in 2006, considering only Schedule II opioids, 0.5% of patients saw 4+ prescribers and 4+ pharmacies (Saunders et al., 2010). A national study found that 13% of patients had overlapping prescriptions from two or more different prescribers during an 18-month period. Of these, 0.5% used 4+ prescribers and 4+ pharmacies (Katz et al., 2010). People who see multiple prescribers or use multiple pharmacies are more likely to die of drug overdoses (Washington State Agency Medical Directors Group, 2010). Data from the California Prescription Drug Monitoring Program (PDMP) indicates that people with higher daily dosages are more likely to see multiple prescribers or go to multiple pharmacies (Cepeda et al., 2012).

The data above suggest that prevention of opioid overdose deaths should focus on strategies that target (1) high-dose opioid users as well as (2) persons who seek care from multiple doctors and pharmacies. The data suggest that these criteria can be considered separately, as measures related to prescribed opioids for legitimate uses versus diverted uses. Thus, PQA proposes 3 measures: one for each criteria (see the related National Quality Measures Clearinghouse [NQMC] measure summary of the PQA measure [Use of opioids from multiple providers or at high dosage in persons without cancer: the proportion of individuals without cancer receiving prescriptions for opioids with a daily dosage greater than 120 mg morphine equivalent dose \(MED\) for 90 consecutive days or longer](#)) and one that is the intersection of both criteria (see the related NQMC measure summary of the PQA measure [Use of opioids from multiple providers or at high dosage in persons without cancer: the proportion of individuals without cancer receiving prescriptions for opioids with a daily dosage greater than 120 mg morphine equivalent dose \(MED\) for 90 consecutive days or longer, AND who received opioid prescriptions from four \(4\) or more prescribers AND four \(4\) or more pharmacies](#)). This approach will also assist health plans in managing the number of patients who meet the measure criteria and planning their respective interventions, so that a balance of identification and intervention can be determined.

## Evidence for Rationale

Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC. Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US. *Drug Saf.* 2012;35(4):325-34. [PubMed](#)

Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. *Ann Intern Med.* 2010 Jan 19;152(2):85-92. [PubMed](#)

Katz N, Panas L, Kim M, Audet AD, Bilansky A, Eadie J, Kreiner P, Paillard FC, Thomas C, Carrow G. Usefulness of prescription monitoring programs for surveillance--analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. *Pharmacoepidemiol Drug Saf.* 2010 Feb;19(2):115-23. [PubMed](#)

Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. *Am J Manag Care*. 2013 Aug;19(8):648-65. [PubMed](#)

Morasco BJ, Duckart JP, Carr TP, Deyo RA, Dobscha SK. Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain. *Pain*. 2010 Dec;151(3):625-32. [PubMed](#)

Office of Disease Prevention and Health Promotion. National action plan for adverse drug event prevention. Washington (DC): U.S. Department of Health and Human Services; 2014. 178 p.

Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG, Harvey W, Loring LD. A history of being prescribed controlled substances and risk of drug overdose death. *Pain Med*. 2012 Jan;13(1):87-95. [PubMed](#)

Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p.

Saunders KW, Dunn KM, Merrill JO, Sullivan M, Weisner C, Braden JB, Psaty BM, Von Korff M. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med*. 2010 Apr;25(4):310-15. [PubMed](#)

Washington State Agency Medical Directors Group. Interagency guideline on opioid dosing for chronic non-cancer pain. Olympia (WA): Washington State Agency Medical Directors Group; 2010. 55 p.

## Primary Health Components

Opioids; multiple prescribers; multiple pharmacies

## Denominator Description

Any member with two or more prescription claims for opioids filled on at least two separate days, for which the sum of the days supply is greater than or equal to 15 (see the related "Denominator Inclusions/Exclusions" field)

## Numerator Description

Any member in the denominator who received opioids from 4 or more prescribers AND 4 or more pharmacies

## Evidence Supporting the Measure

### Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

# Additional Information Supporting Need for the Measure

Unspecified

## Extent of Measure Testing

This measure was pilot tested during measure development (see process below), which included reliability testing.

### Process for Development and Testing of Performance Measures

Step 1: Pharmacy Quality Alliance (PQA) workgroups identify measure concepts that may be appropriate for development into fully specified performance measures. The workgroups focus on specific aspects of the medication-use system and/or specific therapeutic areas. The workgroups are open to all members of PQA and use a consensus-based approach to identify, prioritize and recommend the measure concepts that are deemed to be highly important for supporting quality improvement related to medications.

Step 2: The measure concepts that are recommended for further development through a vote by the PQA workgroups are forwarded to the PQA Quality Metrics Expert Panel (QMEP) for evaluation and refinement. The QMEP reviews the measure concepts to provide an initial assessment of the key properties of performance measures (i.e., feasibility, usability and scientific validity). The measure concepts that are rated highly on these key properties will then undergo technical specification.

Step 3: The draft measure is provided to PQA member organizations for their comments prior to preparing technical specifications for pilot testing. The QMEP reviews member comments, edits the draft measure accordingly and poses testing questions based on this all-member feedback.

Step 4: PQA selects partners to test the draft measure. These partners are often PQA member health plans or academic institutions with expertise in quality and performance measure testing. The testing partner implements the draft technical specifications with their existing datasets and provides a report to PQA that details testing results and recommendations for modifications of the technical specifications.

Step 5: The workgroup that developed the measure reviews the testing results and provides comment. The QMEP reviews the workgroup comments, testing results, recommendations and potential modifications and provides a final assessment of the feasibility and scientific validity of the draft performance measures.

Step 6: Measures that are recommended by the QMEP for endorsement are posted on the PQA Web site for member review, written comments are requested, and a conference call for member organizations is scheduled to address any questions. This process allows members to discuss their views on the measures in advance of the voting period.

Step 7: PQA member organizations vote on the performance measure(s) considered for endorsement.

## Evidence for Extent of Measure Testing

Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p.

## State of Use of the Measure

### State of Use

Current routine use

## Current Use

not defined yet

## Application of the Measure in its Current Use

### Measurement Setting

Managed Care Plans

Other

### Professionals Involved in Delivery of Health Services

not defined yet

### Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

### Statement of Acceptable Minimum Sample Size

Specified

### Target Population Age

Age greater than or equal to 18 years

### Target Population Gender

Either male or female

## National Strategy for Quality Improvement in Health Care

### National Quality Strategy Priority

## Institute of Medicine (IOM) National Health Care Quality Report Categories

### IOM Care Need

Not within an IOM Care Need

## IOM Domain

Not within an IOM Domain

## Data Collection for the Measure

### Case Finding Period

Twelve-month measurement year

### Denominator Sampling Frame

Enrollees or beneficiaries

### Denominator (Index) Event or Characteristic

Patient/Individual (Consumer) Characteristic

Therapeutic Intervention

### Denominator Time Window

not defined yet

### Denominator Inclusions/Exclusions

#### Inclusions

Any member with two or more prescription claims for opioids\* filled on at least two separate days, for which the sum of the days supply is greater than or equal to 15

Note: Eligible Population:

*Ages:* 19 years and older as of the last day of the measurement period.

*Continuous Enrollment Using Enrollment Data:* Subjects should be continuously enrolled during the measurement period.

*Allowable Gap:* No more than one gap in continuous enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 consecutive days] is not considered continuously enrolled).

*Measurement Period:* The patient's measurement period begins on the date of the first fill of the target medication (i.e., index date) and extends through the last day of the enrollment period or until death or disenrollment.

\**Opioid:* Also include tramadol and tapentadol. Refer to Table Opioid-A in the original measure documentation for opioid medications.

#### Exclusions

Any member with Prescription Drug Hierarchical Condition Categories (RxHCCs) 8, 9, 10, 11, or a hospice indicator from the enrollment database (see the original measure documentation for RxHCC list and associated diagnoses).

### Exclusions/Exceptions

not defined yet

### Numerator Inclusions/Exclusions

#### Inclusions

Any member in the denominator who received opioids from 4 or more prescribers AND 4 or more pharmacies

#### Exclusions

Unspecified

## Numerator Search Strategy

Fixed time period or point in time

## Data Source

Administrative clinical data

Electronic health/medical record

Pharmacy data

## Type of Health State

Does not apply to this measure

## Instruments Used and/or Associated with the Measure

Unspecified

## Computation of the Measure

### Measure Specifies Disaggregation

Does not apply to this measure

## Scoring

Rate/Proportion

## Interpretation of Score

Does not apply to this measure (i.e., there is no pre-defined preference for the measure score)

## Allowance for Patient or Population Factors

not defined yet

## Description of Allowance for Patient or Population Factors

This measure requires that separate rates be reported for:

Commercial, Medicaid, Medicare (report each product line separately)

Low income subsidy (LIS) population (report rates for LIS population and non-LIS population separately)

## Standard of Comparison

not defined yet

## Identifying Information

### Original Title

Use of opioids from multiple providers or at high dosage in persons without cancer: measure 2 (multiple prescribers and multiple pharmacies).

### Measure Collection Name

Pharmacy Quality Alliance (PQA) Measures

### Measure Set Name

Medication Safety Measures

### Submitter

Pharmacy Quality Alliance - Clinical Quality Collaboration

### Developer

Pharmacy Quality Alliance - Clinical Quality Collaboration

### Funding Source(s)

None

### Composition of the Group that Developed the Measure

PQA Medication Safe Use Workgroup

Measure development begins in PQA workgroups comprised of individuals appointed by member organizations. Workgroups identify measurement needs within the high-priority areas and/or gaps in existing performance measure sets. Meeting regularly through conference calls, workgroups use a consensus-driven process to draft, refine and recommend high-priority measures of medication.

### Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

## Adaptation

This measure was not adapted from another source.

## Date of Most Current Version in NQMC

2015 Jul

## Measure Maintenance

Annually

## Date of Next Anticipated Revision

2016

## Measure Status

This is the current release of the measure.

## Measure Availability

Source not available electronically.

For more information, contact the Pharmacy Quality Alliance (PQA) at 6213 Old Keene Mill Court, Springfield, VA 22152; Phone: 703-690-1987; Fax: 703-842-8150; Web site: [www.pqaalliance.org](http://www.pqaalliance.org)  
; Email: [info@PQAalliance.org](mailto:info@PQAalliance.org).

## NQMC Status

This NQMC summary was completed by ECRI Institute on April 1, 2016. The information was verified by the measure developer on May 6, 2016.

## Copyright Statement

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

The Pharmacy Quality Alliance (PQA) performance measures and supporting drug code lists may be used for non-commercial use with permission from PQA. Commercial use of the PQA measures requires a licensing agreement. For information contact PQA at [info@PQAalliance.org](mailto:info@PQAalliance.org).

## Production

## Source(s)

Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p.

# Disclaimer

## NQMC Disclaimer

The National Quality Measures Clearinghouse (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.